Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
- Phase 3 NEAR-1 and NEAR-2 clinical trials met primary and key secondary endpoints - Presbyopia is the loss of ability to focus on near objects as a result of…